Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial Carcinoma - PubMed
3 hours ago
- #enfortumab vedotin
- #dexamethasone
- #urothelial carcinoma
- First-line enfortumab vedotin plus pembrolizumab (EVP) with dexamethasone premedication was studied in advanced urothelial carcinoma.
- The study included 77 patients, median age 75, with over half ineligible for pivotal trials.
- Cutaneous toxicity was common (52.0%) but severe skin reactions were rare (3.9%).
- Objective response rate was 73.0%, with 6-month progression-free survival at 73.9% and overall survival at 78.7%.
- EVP with dexamethasone premedication showed manageable toxicity and promising early effectiveness, even in patients with comorbidities.
- Longer follow-up and prospective studies are needed to assess long-term outcomes and dexamethasone's impact.